Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 479-498, September 2007

Chemoimmunotherapy of chronic lymphocytic leukemia

Leukemia Department, Unit 428, The University of Texas MD Anderson Cancer, 1515 Holcombe Blvd, Center Houston, Texas 77025, USA

The past two decades have seen a major paradigm shift in the therapy of chronic lymphocytic leukemia (CLL), with the treatment goal shifting from symptom palliation to the attainment of maximal disease control using the most effective frontline regimens available, thus prolonging survival and possibly leading to cure. The most potent therapeutic regimens developed to date include the chemoimmunotherapy combinations incorporating purine analogs and monoclonal antibodies. We review the evolution of modern chemoimmunotherapy for CLL, and discuss current research directions for further refining the potency of these regimens.

Key words: purine analog, rituximab, alemtuzumab, monoclonal antibody, fludarabine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(07)00020-5

doi:10.1016/j.beha.2007.02.004

Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 479-498, September 2007

Article Tools

* Image Usage & Resolution